Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × quemliclustat × Gastrointestinal × Clear all
NCT04104672 2026-06-02

ARC-8

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
196 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-06-02

EDGE-Gastric

Arcus Biosciences, Inc.

Phase 2 Active not recruiting
332 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06608927 2026-06-02

PRISM-1

Arcus Biosciences, Inc.

Phase 3 Active not recruiting
610 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed
227 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡